Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.

Tamura T, Noda H, Joyashiki E, Hoshino M, Watanabe T, Kinosaki M, Nishimura Y, Esaki T, Ogawa K, Miyake T, Arai S, Shimizu M, Kitamura H, Sato H, Kawabe Y.

Nat Commun. 2016 Nov 18;7:13384. doi: 10.1038/ncomms13384.

2.

Bone Morphogenetic Protein 4 and Smad1 Mediate Extracellular Matrix Production in the Development of Diabetic Nephropathy.

Matsubara T, Araki M, Abe H, Ueda O, Jishage K, Mima A, Goto C, Tominaga T, Kinosaki M, Kishi S, Nagai K, Iehara N, Fukushima N, Kita T, Arai H, Doi T.

Diabetes. 2015 Aug;64(8):2978-90. doi: 10.2337/db14-0893. Epub 2015 May 20.

3.

Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.

Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R.

J Biol Chem. 2004 Feb 27;279(9):8269-77. Epub 2003 Dec 15.

4.

The TNF receptor superfamily: role in immune inflammation and bone formation.

Cheng X, Kinosaki M, Murali R, Greene MI.

Immunol Res. 2003;27(2-3):287-94. Review.

PMID:
12857975
5.

Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.

Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K.

J Bone Miner Metab. 2002;20(6):337-44.

PMID:
12434161
6.

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production.

Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N.

J Biol Chem. 2003 Jan 24;278(4):2206-11. Epub 2002 Nov 4.

7.

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T.

J Exp Med. 2000 Jan 17;191(2):275-86.

8.

A novel molecular mechanism modulating osteoclast differentiation and function.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K.

Bone. 1999 Jul;25(1):109-13.

PMID:
10423033
9.

A mutant of deleted variant of hepatocyte growth factor (dHGF) with alanine substitution in the N-terminal basic region has higher activity in vivo.

Kinosaki M, Yamaguchi K, Yamashita Y, Uematsu Y, Aihara H, Masunaga H, Morinaga T, Higashio K.

Biochem Biophys Res Commun. 1999 Jan 19;254(2):363-7.

PMID:
9918843
10.

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K.

Biochem Biophys Res Commun. 1998 Dec 18;253(2):395-400.

PMID:
9878548
11.

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N.

Biochem Biophys Res Commun. 1998 Sep 18;250(2):229-34.

PMID:
9753612
13.

Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.

Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K.

Biochem Biophys Res Commun. 1998 May 19;246(2):337-41.

PMID:
9610359
14.

Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF).

Kinosaki M, Yamaguchi K, Murakami A, Ueda M, Morinaga T, Higashio K.

Biochim Biophys Acta. 1998 Apr 23;1384(1):93-102.

PMID:
9602078
15.

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602.

16.

Characterization of structural domains of human osteoclastogenesis inhibitory factor.

Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K.

J Biol Chem. 1998 Feb 27;273(9):5117-23.

17.

Intracellular localization of UDP-glucuronosyltransferase expressed from the transfected cDNA in cultured cells.

Kinosaki M, Masuko T, Sogawa K, Iyanagi T, Yamamoto T, Hashimoto Y, Fujii-Kuriyama Y.

Cell Struct Funct. 1993 Feb;18(1):41-51.

18.

A novel species of cytochrome P-450 (P-450ib) specific for the small intestine of rabbits. cDNA cloning and its expression in COS cells.

Kikuta Y, Sogawa K, Haniu M, Kinosaki M, Kusunose E, Nojima Y, Yamamoto S, Ichihara K, Kusunose M, Fujii-Kuriyama Y.

J Biol Chem. 1991 Sep 25;266(27):17821-5.

19.

cDNA cloning and expression of the mRNA for cytochrome P-450kd which shows a fatty acid omega-hydroxylating activity.

Yokotani N, Kusunose E, Sogawa K, Kawashima H, Kinosaki M, Kusunose M, Fujii-Kuriyama Y.

Eur J Biochem. 1991 Mar 28;196(3):531-6.

Supplemental Content

Loading ...
Support Center